Tag Archives: Cory Kasimov

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and IMV (NASDAQ: IMV)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN – Research Report) and IMV (IMV – Research Report). Amgen (AMGN) In a report issued on January 14, Cory Kasimov from

Moderna (MRNA) Receives a Buy from J.P. Morgan

In a report issued on January 10, Cory Kasimov from J.P. Morgan maintained a Buy rating on Moderna (MRNA – Research Report). The company’s shares closed last Monday at $20.26. According to TipRanks.com, Kasimov is a 4-star analyst with an

J.P. Morgan Maintains a Hold Rating on NovoCure (NVCR)

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on NovoCure (NVCR – Research Report) yesterday. The company’s shares closed last Monday at $81.20. According to TipRanks.com, Kasimov is a 4-star analyst with an average return of 6.1% and a

J.P. Morgan Issues a Buy Rating on Vertex Pharmaceuticals (VRTX)

In a report released yesterday, Cory Kasimov from J.P. Morgan assigned a Buy rating to Vertex Pharmaceuticals (VRTX – Research Report). The company’s shares closed last Monday at $226.49, close to its 52-week high of $233.26. According to TipRanks.com, Kasimov

J.P. Morgan Reaffirms Their Hold Rating on Regeneron (REGN)

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Regeneron (REGN – Research Report) yesterday. The company’s shares closed last Monday at $378.93. According to TipRanks.com, Kasimov is a 4-star analyst with an average return of 6.1% and a

Incyte (INCY) Receives a Buy from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Incyte (INCY – Research Report) yesterday. The company’s shares closed last Monday at $77.10. According to TipRanks.com, Kasimov is a 4-star analyst with an average return of 6.1% and a